Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Fitzpatrick

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
European Journal of Human Genetics : EJHG|September 11, 2008
Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study)Linda T Roten, Matthew P Johnson, Siri Forsmo, et al.
Plos One|September 10, 2019
A systematic review and network meta-analysis of existing pharmacologic therapies in patients with idiopathic sudden sensorineural hearing lossNadera Ahmadzai, Shaun Kilty, Wei Cheng, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancerGary K Koski, Ursula Koldovsky, Shuwen Xu, et al.
Cancer|January 19, 2012
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situAnupama Sharma, Ursula Koldovsky, Shuwen Xu, et al.
Viruses|July 27, 2022
Cardiopulmonary Injury in the Syrian Hamster Model of COVID-19Yi Xue, Dong Yang, Peter Vogel, et al.
Breast Cancer Research : BCR|May 23, 2015
Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancerJashodeep Datta, Erik Berk, Shuwen Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2016
Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2<sup>pos</sup> DCIS Independent of Route: Results of Randomized Selection Design TrialLea Lowenfeld, Rosemarie Mick, Jashodeep Datta, et al.
Critical Care Medicine|August 16, 2014
Deficiency of the two-pore-domain potassium channel TREK-1 promotes hyperoxia-induced lung injuryAndreas Schwingshackl, Bin Teng, Patrudu Makena, et al.
Oncoimmunology|September 22, 2017
Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER<sup>pos</sup>/HER2<sup>pos</sup> early breast cancerLea Lowenfeld, Salman Zaheer, Crystal Oechsle, et al.
European Journal of Human Genetics : EJHG|October 10, 2013
Mutations in SH3PXD2B cause Borrone dermato-cardio-skeletal syndromeGabrielle R Wilson, Jasmine Sunley, Katherine R Smith, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
European Journal of Human Genetics : EJHG|September 11, 2008
Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study)Linda T Roten, Matthew P Johnson, Siri Forsmo, et al.
Plos One|September 10, 2019
A systematic review and network meta-analysis of existing pharmacologic therapies in patients with idiopathic sudden sensorineural hearing lossNadera Ahmadzai, Shaun Kilty, Wei Cheng, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancerGary K Koski, Ursula Koldovsky, Shuwen Xu, et al.
Cancer|January 19, 2012
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situAnupama Sharma, Ursula Koldovsky, Shuwen Xu, et al.
Viruses|July 27, 2022
Cardiopulmonary Injury in the Syrian Hamster Model of COVID-19Yi Xue, Dong Yang, Peter Vogel, et al.
Breast Cancer Research : BCR|May 23, 2015
Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancerJashodeep Datta, Erik Berk, Shuwen Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2016
Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2<sup>pos</sup> DCIS Independent of Route: Results of Randomized Selection Design TrialLea Lowenfeld, Rosemarie Mick, Jashodeep Datta, et al.
Critical Care Medicine|August 16, 2014
Deficiency of the two-pore-domain potassium channel TREK-1 promotes hyperoxia-induced lung injuryAndreas Schwingshackl, Bin Teng, Patrudu Makena, et al.
Oncoimmunology|September 22, 2017
Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER<sup>pos</sup>/HER2<sup>pos</sup> early breast cancerLea Lowenfeld, Salman Zaheer, Crystal Oechsle, et al.
European Journal of Human Genetics : EJHG|October 10, 2013
Mutations in SH3PXD2B cause Borrone dermato-cardio-skeletal syndromeGabrielle R Wilson, Jasmine Sunley, Katherine R Smith, et al.
Pageof 6